Back

Which treatment attributes do patients with transthyretin amyloid cardiomyopathy value most?

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy (2) Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Mrs Anne Carr

Hagersville (Canada)

5 More presentations in this session

Presentation thumbnail
Using dapagliflozin to reduce NT-proBNP and improve symptom in transthyretin cardiac amyloidosis - a series of n-of-1 trials pilot study
Doctor E. Haakansson (Umea, SE)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics and outcomes in a cohort of patients starting treatment with vericiguat in the US.
Doctor A. Michel (Basel, CH)
Abstract Slides Video
Presentation thumbnail
The care-gap for women living with heart failure
Doctor O. Graham (Craigavon, GB)
Abstract Slides Video
Presentation thumbnail
Intermittent levosimendan therapy and survival outcomes in advanced heart failure: insights from a real-world single-centre study
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Ambulatory blood pressure monitoring reveals true significant hypotension in stable HF patients; Is this an overlooked issue?
Doctor G. Bruno (Limerick, IE)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy (2)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Session
Cardiac amyloidosis from epidemiology to treatment
thumbnail
Congress Session
Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment
thumbnail
Congress Session
Advances in amyloidosis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources